{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:09:44Z","timestamp":1789139384055,"version":"build-2803163510"},"reference-count":26,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Parkinson\u2019s Disease"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Developers of disease-modifying therapies (DMTs) for early-stage Parkinson's are in dialogue with regulators to identify the relative merits of the Movement Disorder Society \u2013 Unified Parkinson's Disease Rating Scale (MDS-UPDRS) for detecting clinically meaningful changes in patients\u2019 daily functioning during early-stage disease. We report the first qualitative assessment of MDS-UPDRS part III items\u2019 clinical meaningfulness for use in DMT pivotal trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Semi-structured interviews were conducted with 40 patients and 20 movement disorder neurologists. Evidence was synthesized using an interpretation framework to evaluate items according to four appraisal components.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Based on synthesized evidence for each appraisal component:\n                      <jats:list list-type=\"order\">\n                        <jats:list-item>\n                          <jats:p>\n                            Patient feedback indicated all items were at least somewhat\n                            <jats:bold>meaningful to patients<\/jats:bold>\n                            ; 12\/18 items were classified as \u201chighly meaningful\u201d given their linkage to motor\/daily activities functioning. See\n                            <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/journals.sagepub.com\/doi\/full\/10.1177\/1877718X261453177#supplementary-materials-1\">\n                              <jats:bold>Interactive Supplement<\/jats:bold>\n                            <\/jats:ext-link>\n                            .\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            4\/18 items were endorsed by &gt;90% of neurologists as\n                            <jats:bold>clinically relevant in early-stage Parkinson's<\/jats:bold>\n                            (\u201chighly relevant\u201d).\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Evidence from neurologists was supportive of 6\/18 items in terms of their\n                            <jats:bold>usefulness for capturing disease progression<\/jats:bold>\n                            (\u201chighly useful\u201d).\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            Neurologist feedback suggested\n                            <jats:bold>response option distinction\/assessment specificity<\/jats:bold>\n                            is inconsistent across items.\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                    <jats:p>Together, qualitative evidence endorsed the value of items 3.3 Rigidity, 3.4 Finger tapping, 3.5 Hand movements, 3.6 Pronation-supination, 3.7 Toe tapping, and 3.8 Leg agility across all four appraisal components.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A subset of limb-related rigidity\/bradykinesia items may be most clinically meaningful for detecting changes in early-stage Parkinson's. Consolidation of quantitative data with evidence from this large qualitative sample will inform final decision-making for a primary efficacy outcome measure in DMT pivotal trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1877718x261453177","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T13:53:29Z","timestamp":1785160409000},"page":"1223-1240","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Qualitative assessment of the clinical meaningfulness of MDS-UPDRS part III items in early-stage Parkinson's"],"prefix":"10.1177","volume":"16","author":[{"given":"Sophie","family":"Cleanthous","sequence":"first","affiliation":[{"name":"Modus Outcomes"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8843-7730","authenticated-orcid":false,"given":"Roger A","family":"Barker","sequence":"additional","affiliation":[{"name":"University of Cambridge"},{"name":"Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milton","family":"Biagioni","sequence":"additional","affiliation":[{"name":"UCB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7974-9588","authenticated-orcid":false,"given":"David T","family":"Dexter","sequence":"additional","affiliation":[{"name":"Parkinson's UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2347-1644","authenticated-orcid":false,"given":"Tanya","family":"Simuni","sequence":"additional","affiliation":[{"name":"Northwestern University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0690-5359","authenticated-orcid":false,"given":"Thomas","family":"Morel","sequence":"additional","affiliation":[{"name":"UCB, Bulle, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00038-3"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-240272"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-024-00716-z"},{"key":"e_1_3_3_5_2","volume-title":"BEST (Biomarkers, EndpointS, and other Tools) Resource","author":"FDA-NIH Biomarker Working Group. Validation","year":"2016","unstructured":"FDA-NIH Biomarker Working Group. Validation. BEST (Biomarkers, EndpointS, and other Tools) Resource. Silver Spring (MD), Bethesda (MD): Food and Drug Administration (US), National Institutes of Health (US), 2016."},{"key":"e_1_3_3_6_2","unstructured":"U.S. Food and Drug Administration. Demonstrating substantial evidence of effectiveness for human drug and biological products https:\/\/www.fda.gov\/media\/133660\/download (2019 accessed 19 February 2026)."},{"key":"e_1_3_3_7_2","unstructured":"U.S. Food and Drug Administration. Patient-focused drug development: incorporating clinical outcome assessments into endpoints for regulatory decision-making https:\/\/www.fda.gov\/media\/166830\/download (2023 accessed 19 February 2026)."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22340"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09348-3"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.98.18_supplement.157"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00375-3"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-202457"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-025-00907-2"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-025-01072-2"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-230446"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.4324\/9780203413081"},{"key":"e_1_3_3_17_2","volume-title":"Research methods in health: investigating health and health services","author":"Bowling A","year":"2009","unstructured":"Bowling A. Research methods in health: investigating health and health services. 3rd ed. Maidenhead: Open University Press, 2009.","edition":"3"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1191\/1478088706qp063oa"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-225122"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-225068"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.27224"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.28110"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.29154"},{"key":"e_1_3_3_24_2","volume-title":"Optimization of MDS-UPDRS for use in early-stage Parkinson's disease clinical trialsPresented at the 16th Annual Parkinson's Disease Therapeutics Conference (PDTC)","author":"Morel T","unstructured":"Morel T, Kopil K, Ayasse C, et al. Optimization of MDS-UPDRS for use in early-stage Parkinson's disease clinical trials. In: Presented at the 16th Annual Parkinson's Disease Therapeutics Conference (PDTC), October 17, 2024."},{"key":"e_1_3_3_25_2","unstructured":"Critical Path Institute. Critical Path for Parkinson's. https:\/\/c-path.org\/program\/critical-path-for-parkinsons\/#overview- (accessed 19 February 2026)."},{"key":"e_1_3_3_26_2","volume-title":"Optimizing use of MDS-UPDRS for clinical trial endpoints in early-stage Parkinson\u2019sPresented at the 33rd Annual Parkinson Study Group Meeting (PSG)","author":"Ayasse N","unstructured":"Ayasse N, Coon C, L\u2019italien G, et al. Optimizing use of MDS-UPDRS for clinical trial endpoints in early-stage Parkinson\u2019s. In: Presented at the 33rd Annual Parkinson Study Group Meeting (PSG), December 5\u20138, 2024."},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1037\/qup0000145"}],"container-title":["Journal of Parkinson\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1877718X261453177","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1877718X261453177","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1877718X261453177","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T14:14:05Z","timestamp":1789136045000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1877718X261453177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1177\/1877718X261453177"],"URL":"https:\/\/doi.org\/10.1177\/1877718x261453177","relation":{},"ISSN":["1877-7171","1877-718X"],"issn-type":[{"value":"1877-7171","type":"print"},{"value":"1877-718X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]}}}